Literature DB >> 18833457

Bipolar affective disorder and medication therapy: identifying barriers.

Adriana Inocenti Miasso1, Silvia Helena De Bortoli Cassiani, Luiz Jorge Pedrão.   

Abstract

This study identified the barriers faced by people with bipolar affective disorder (BAD) regarding the need for continuous medication. The qualitative approach was used, and the methodological framework was based on the Grounded Theory in the light of Symbolic Interactionism. In total, of 14 people with BAD, who were being attended at the Outpatient Unit for Mood Disorders of a university hospital, and 14 relatives indicated by them participated in the study. The data collection was carried out through interviews and observation. Two categories emerged from the results, describing the barriers faced by people with BAD: to have affective and cognitive losses and to have several limitations. People with BAD feel ambivalent regarding medication adherence, as they perceive that, no matter the direction they take, it will lead to a context of prejudice, losses and limitations in various spheres of daily life.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18833457     DOI: 10.1590/s0104-11692008000400014

Source DB:  PubMed          Journal:  Rev Lat Am Enfermagem        ISSN: 0104-1169


  2 in total

1.  Psycho-demographic and clinical predictors of medication adherence in patients with bipolar I disorder in a university hospital in Egypt.

Authors:  Tarek A Okasha; Doaa N Radwan; Hussien Elkholy; Heba M F M Hendawy; Eman M M E Shourab; Ramy R A Teama; Ahmed S Abdelgawad
Journal:  S Afr J Psychiatr       Date:  2020-02-10       Impact factor: 1.550

Review 2.  Bipolarity and suicidal ideation in children and adolescents: a systematic review with meta-analysis.

Authors:  Flórido Sampaio das Neves Peixoto; Danilo Ferreira de Sousa; Dayse Christina Rodrigues Pereira Luz; Nélio Barreto Vieira; Jucier Gonçalves Júnior; Gabriel Cabral Alencar Dos Santos; Flaviane Cristine Troglio da Silva; Modesto Leite Rolim Neto
Journal:  Ann Gen Psychiatry       Date:  2017-04-21       Impact factor: 3.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.